EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts

Afreen Jasim, Winston Lee, Huiyan Ma, Elizabeth Quirk, Joo Song, Scott Hwee, Jessica Hughes, Parastou Tizro, Lori Soma

American Journal of Clinical Pathology · 19.11.2025 · 164 (5) · 694-703

DOI: 10.1093/ajcp/aqaf087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 17.09.2025. Verfasst von Afreen Jasim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, City of Hope Medical Center, Durate, CA, United States. Hauptthemen laut MEDLINE: Tetraspanin 29, Leukemia, Myeloid, Acute, Bone Marrow Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Research on CD9 expression has been extensive in B lymphoblastic leukemia, with fewer studies focusing on acute myeloid leukemia (AML). We investigated the usefulness of CD9 in differentiating normal from abnormal myeloid progenitors, as well as expression in normal cell types and in AML.

Methods

Flow cytometry was used to assess the level of CD9 expression on normal and leukemic myeloid blasts and other normal bone marrow populations. Geometric mean fluorescence intensity levels and expression patterns were compared among cell types and AML subtypes.

Results

In normal subsets (n = 69), the level of CD9 expression was lowest in mature B cells, myeloid blasts, promyelocytes, and neutrophils, with intermediate expression in monocytes and highest in hematogones (stages 1 and 2). Committed myeloid progenitors (CMPs) had lower expression than hematopoietic stem cells (HSCs). CD9 typically has higher expression in AML (n = 58) compared to normal myeloid blasts and promyelocytes, and it is differentially expressed in AML, with the highest expression in PML::RARA AML.

Conclusions

Aberrant CD9 expression can be useful differentiating normal from abnormal myeloid progenitors, with the highest level of expression in AML with PML::RARA in our cohort. There was differential expression between HSCs and CMPs in the small numbers studied. Normal mature B cells can be used as an internal negative control in most cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tetraspanin 29Leukemia, Myeloid, AcuteBone Marrow CellsHumansFlow CytometryMaleFemaleMiddle AgedBiomarkers, TumorAdult

Stichwörter der Autor:innen

CD9acute myeloid leukemiaflow cytometryhematopoietic stem cellsnormal myeloid blasts

Substanzen

Tetraspanin 29CD9 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, City of Hope Medical Center, Durate, CA, United States.
  • Department of Computation and Quantitative Medicine, Beckman Research Institute, City of Hope Medical Center, Duarte CA, United States.

Zitieren

APA

Jasim, A., Lee, W., Ma, H., Quirk, E., Song, J., Hwee, S., Hughes, J., Tizro, P., & Soma, L. (2025). CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts. American Journal of Clinical Pathology, 164(5), 694-703. https://doi.org/10.1093/ajcp/aqaf087

Vancouver

Jasim A, Lee W, Ma H, Quirk E, Song J, Hwee S, et al. CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts. American Journal of Clinical Pathology. 2025;164(5):694-703. doi:10.1093/ajcp/aqaf087

BibTeX
@article{Jasim2025,
  author = {Jasim, Afreen and Lee, Winston and Ma, Huiyan and Quirk, Elizabeth and Song, Joo and Hwee, Scott and Hughes, Jessica and Tizro, Parastou and Soma, Lori},
  title = {CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  volume = {164},
  number = {5},
  pages = {694--703},
  doi = {10.1093/ajcp/aqaf087}
}
Kostenlos starten →